Skip to main content
. 2016 Sep 22;29(6):643–655. doi: 10.1111/pcmr.12512

Figure 2.

Figure 2

Canine melanomas exhibit a diverse range of ERK1/2 and AKT activities. To explore the potential of targeting MEK and PI3K/mTOR signaling cascades in canine melanomas, the activation status of effectors ERK1/2 and AKT, respectively, were analyzed by WB in (A) a panel of primary canine melanomas and (B) cell lines derived from canine melanomas. *Specimens or cell lines harboring N‐RAS Q61 mutation. No other RAS or BRAF hot spot mutations were found. Lane numbers indicate unique canine patient primary tumor samples.